KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Accounts Payables (2016 - 2025)

Sarepta Therapeutics has reported Accounts Payables over the past 15 years, most recently at $280.8 million for Q4 2025.

  • Quarterly results put Accounts Payables at $280.8 million for Q4 2025, up 30.96% from a year ago — trailing twelve months through Dec 2025 was $280.8 million (up 30.96% YoY), and the annual figure for FY2025 was $280.8 million, up 30.96%.
  • Accounts Payables for Q4 2025 was $280.8 million at Sarepta Therapeutics, up from $94.0 million in the prior quarter.
  • Over the last five years, Accounts Payables for SRPT hit a ceiling of $280.8 million in Q4 2025 and a floor of $44.2 million in Q3 2021.
  • Median Accounts Payables over the past 5 years was $101.3 million (2022), compared with a mean of $113.4 million.
  • Peak annual rise in Accounts Payables hit 188.22% in 2021, while the deepest fall reached 40.74% in 2021.
  • Sarepta Therapeutics' Accounts Payables stood at $76.7 million in 2021, then rose by 24.93% to $95.9 million in 2022, then skyrocketed by 72.01% to $164.9 million in 2023, then surged by 30.03% to $214.4 million in 2024, then skyrocketed by 30.96% to $280.8 million in 2025.
  • The last three reported values for Accounts Payables were $280.8 million (Q4 2025), $94.0 million (Q3 2025), and $136.7 million (Q2 2025) per Business Quant data.